| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2014-02-07 |
| タイトル |
|
|
タイトル |
Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Alternative splicing |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
BCR-ABL1 |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Chronic myelogenous leukemia |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Mutation |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Resistance |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Itonaga, Hidehiro
Tsushima, Hideki
Imanishi, Daisuke
Hata, Tomoko
Doi, Yuko
Mori, Sayaka
Sasaki, Daisuke
Hasegawa, Hiroo
Matsuo, Emi
Nakashima, Jun
Kato, Takeharu
Horai, Makiko
Taguchi, Masataka
Matsuo, Masatoshi
Taniguchi, Hiroaki
Makiyama, Junnya
Sato, Shinya
Horio, Kensuke
Ando, Koji
Moriwaki, Yuji
Sawayama, Yasushi
Ogawa, Daisuke
Yamasaki, Reishi
Takasaki, Yumi
Imaizumi, Yoshitaka
Taguchi, Jun
Kawaguchi, Yasuhisa
Yoshida, Shinichiro
Joh, Tatsuro
Moriuchi, Yukiyoshi
Nonaka, Hiroaki
Soda, Hisashi
Fukushima, Takuya
Nagai, Kazuhiro
Kamihira, Shimeru
Tomonaga, Masao
Yanagihara, Katsunori
Miyazaki, Yasushi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
An appropriate trigger for BCR-ABL1 mutation analysis has not yet been established in unselected cohorts of chronic-phase chronic myelogenous leukemia patients. We examined 92 patients after 12 months of tyrosine kinase inhibitor (TKI) treatment in Nagasaki Prefecture, Japan. Univariate analysis revealed that significant factors associated with not attaining a major molecular response (MMR) were the presence of the minor BCR-ABL1 fusion gene, a low daily dose of TKI, and the emergence of BCR-ABL1 kinase domain mutations conferring resistance to imatinib. Factors associated with the loss of sustained MMR were a low daily dose of TKI and the emergence of alternatively spliced BCR-ABL1 mRNA with a 35-nucleotide insertion. Taken together, our results suggest that the search for BCR-ABL1 mutations should be initiated if patients have not achieved MMR following 12 months of TKI treatment. |
| 書誌情報 |
Leukemia Research
巻 38,
号 1,
p. 76-83,
発行日 2014-01
|
| 出版者 |
|
|
出版者 |
Elsevier Limited |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
01452126 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1016/j.leukres.2013.10.022 |
| 権利 |
|
|
権利情報 |
c 2013 Elsevier Ltd. |
| 権利 |
|
|
権利情報 |
NOTICE: this is the author’s version of a work that was accepted for publication in Leukemia Research. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Leukemia Research, 38, ISS1, (2014) |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Leukemia Research, 38(1), pp.76-83; 2014 |
LeuRes38_76.pdf (1.1 MB)
